Patent ID: 6030960
Filing Date: 2000-02-29
Classification: A61K,A61P,Y02A,Y10S

Abstract:
A method of inhibiting the production of hepatitis virus-induced antigens in a human subject, said method comprising administering an antigen inhibiting amount of a compound of Formula I: ##STR7## wherein Y is S, O, NH, NCH.sub.3, NHC(O), or NCH.sub.3 C(O);R.sub.1 is unbranched or branched, saturated or unsaturated C1-C20 alkyl, alkenyl, or alkynyl;X is a covalent bond or methylene optionally substituted with hydroxyl, C1-C20 alkyl, C1-C20 alkoxy, C1-C20 alkylthio or C1-C20 alkylamido;and D is selected from the group consisting of Formula V and Formula VI;wherein Formula V is--(PO.sub.4).sup.- --E (V)wherein E is selected from the group consisting of:--J--N.sup.+ (R.sub.2)(R.sub.3)(R.sub.4),wherein J is C1-C4 alkyl optionally substituted one to three times with methyl or ethyl; and R.sub.2, R.sub.3, and R.sub.4 are independently selected from the group consisting of H and C1-C3 alkyl; anda nucleic acid base conjugate of the Formula VII ##STR8## wherein the base is selected from the group consisting of thymine, adenine, cytosine, guaninie, hypoxanthine, uracil, 2'-3'-dideoxy-3'-thiacytidine, and 2-aminoadenine; A is H, fluorine, or N.sub.3 ; and B is H or fluorine, or A and B together form a covalent bond;and wherein Formula VI is--N.sup.+ (R.sub.5)(R.sub.6)--J--W Z.sup.- (VI)wherein R.sub.5 and R.sub.6 are independently selected from the group consisting of H and C1-C3 alkyl;J is as defined above;W is --OH, or --SH; andZ.sup.- is an anion;or a pharmaceutical salt thereof.